# CHAMPIONS ONCOLOGY, INC. (CSBR) · Edgar & Edgarette company card

> Champions Oncology (CSBR) grew revenue 4.4% in FY2026 to $59 million, operating margin -1.9% against a -15.8% median for biological products, (no diagnostic substances), equity 14.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 771856 · fiscal year ended 2026-04-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/CSBR) · [JSON](https://www.pops4.com/boards/company/CSBR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $59M |
| Revenue growth, 1 year | 4.4% |
| Revenue growth per year | 4.9% |
| Operating margin | -1.9% (prior year 8.0%) |
| Net margin | -2.0% |
| Operating cash flow | −$4M |
| Capital spending | $564,000 |
| Free cash flow | −$5M |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $27M |
| Total equity | $4M |
| Equity ÷ assets | 14.6% |
| Return on equity | -29.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -10.07 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -1.9% in FY2026; revenue is hard to predict: its 80% range is ±30%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $59.4M (FY2026). Experience: revenue up 4.4% on the year, up 4.9% a year over 4 years; operating margin -1.9%, down from 8.0%. Soundness: equity 14.6% of assets, return on equity -29.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $43.9M and $81.4M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $45.0M to $79.7M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -1.9% against a -15.8% median; growth 4.4% against 21.4%.

Range logged 2026-09-24, receipt 05f95660b23800c9, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-03-30 ([filing](https://www.sec.gov/Archives/edgar/data/771856/000162828026021941/0001628280-26-021941-index.htm))

## Recent filings

- 8-K · filed 2026-10-16 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/771856/000162828026066087/0001628280-26-066087-index.htm)
- 10-Q · filed 2026-09-11 · [filing](https://www.sec.gov/Archives/edgar/data/771856/000162828026061519/0001628280-26-061519-index.htm)
- 8-K · filed 2026-09-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/0001628280-26-061383-index.htm)
- DEF 14A · filed 2026-08-28 · [filing](https://www.sec.gov/Archives/edgar/data/771856/000162828026059373/0001628280-26-059373-index.htm)
- 10-K · filed 2026-07-27 · [filing](https://www.sec.gov/Archives/edgar/data/771856/000162828026049834/0001628280-26-049834-index.htm)
- 8-K · filed 2026-07-27 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/771856/000162828026049822/0001628280-26-049822-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000771856.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=771856

## Cite

POPS4, Edgar & Edgarette: CHAMPIONS ONCOLOGY, INC. (CSBR) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CSBR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.